Opioid Modulation With Buprenorphine/Samidorphan as Adjunctive Treatment for Inadequate Response to Antidepressants: A Randomized Double-Blind Placebo-Controlled Trial
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Major depressive disorder has been associated with dysregulation of the endogenous opioid system. The authors sought to determine whether opioid modulation achieved through administration of ALKS 5461, a combination of a μ- and κ-opioid partial agonist, buprenorphine, and a μ-opioid antagonist, samidorphan, would exhibit antidepressant activity in patients with major depression. METHOD: A multicenter, randomized, double-blind, placebo-controlled, two-stage sequential parallel comparison design study was conducted in adults with major depression who had an inadequate response to one or two courses of antidepressant treatment. Participants were randomly assigned to receive adjunctive treatment with 2 mg/2 mg of buprenorphine/samidorphan (the 2/2 dosage group), 8 mg/8 mg of buprenorphine/samidorphan (the 8/8 dosage group), or placebo. Antidepressant effect was measured based on change from baseline to the end of 4 weeks of treatment on the 17-item Hamilton Depression Rating Scale (HAM-D), the Montgomery-Åsberg Depression Rating Scale (MADRS), and the Clinical Global Impressions severity scale (CGI-S). RESULTS: Compared with the placebo group, there were significantly greater improvements in the 2/2 dosage group across the three depression outcome measures (HAM-D: -2.8, 95% CI=-5.1, -0.6; MADRS: -4.9, 95% CI=-8.2, -1.6; CGI-S: -0.5, 95% CI=-0.9, -0.1). There was also evidence of improvement in the 8/8 dosage group, although it did not achieve statistical significance. Overall, the buprenorphine/samidorphan combinations were well tolerated, and there was no evidence of opioid withdrawal on treatment discontinuation. CONCLUSIONS: The buprenorphine/samidorphan combination is a novel and promising candidate for treatment of major depressive disorder in patients who have an inadequate response to standard antidepressants.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A review of eight MST studies reported remission rates ranging from 30% to 40%, and no significant cognitive side effects related to MST 190 .”
From Major depressive disorder (2016) · cites this paper as [190]
In the citing paper
“A review of eight MST studies reported remission rates ranging from 30% to 40%, and no significant cognitive side effects related to MST 190 .”
From Major depressive disorder (2016) · cites this paper as [190]
In the citing paper
“Buprenorphine has antidepressant effects when used for both opioid use disorder and treatment-resistant depression (279-284)”
From A brain-centric model of suicidal behavior (2020) · cites this paper as [282]
In the citing paper
“Overall, six clinical trials [41,42,43,44,45,46]—of which three were randomized, double-blind and placebo controlled studies [41,44,45]—and one clinical case [47], including a total of 216 subjects with TRD treated with BUP in mono-therapy or together with an opioid antagonist (naloxone or samidorphan) were included.”
From The Efficacy of Buprenorphine in Major Depression, Treatment-Resistant Depression and Suicidal Behavior: A Systematic Review (2018) · cites this paper as [45]
In the citing paper
“According to specific studies [22,45], BUP in co-administration with opiate antagonists, such as samidorphan, are able to significantly reduce depression symptoms, NSSI, and suicidal ideation.”
From The Efficacy of Buprenorphine in Major Depression, Treatment-Resistant Depression and Suicidal Behavior: A Systematic Review (2018) · cites this paper as [45]
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817 · cited 1×
“The primary outcome measure was the change in HAM-D score (30) from baseline to the end of the 4-week treatment period.”
BackgroundWARE, J. E., KOSINSKI, M., & KELLER, S. D. (1996) · Medical Care · doi:10.1097/00005650-199603000-00003 · Cited by 17,392
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962 · cited 1×
“Secondary outcome measures were the change from baseline to the end of the 4-week treatment period inMADRS score (31) and Clinical Global Impressions severity scale (CGI-S) score (32), rate of response (defined as a reduction $50% in HAM-D or MADRS score from baseline to week 4), and rate of remission (defined as a HA…”
MethodRush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
Self-citationPosner, K., Brown, G. K., Stanley, B., Brent, D. A., Yershova, K. V., Oquendo, M. A., Currier, G. W., Melvin, G. A., Greenhill, L., Shen, S., et al. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10111704 · Cited by 5,157
Small sample inference for fixed effects from restricted maximum likelihood
Kenward, M. G., & Roger, J. H. (1997) · Biometrics · doi:10.2307/2533558 · Cited by 4,552 · cited 1×
“The Kenward-Roger approximation (38) was used to adjust the denominator degrees of freedom.”
MethodThe Inventory of Depressive Symptomatology (IDS): Psychometric properties
Rush, A. J., Gullion, C. M., Basco, M. R., Jarrett, R. B., & Trivedi, M. H. (1996) · Psychological Medicine · doi:10.1017/s0033291700035558 · Cited by 2,177
Self-citationECDEU Assessment Manual: (591322011-001)
Guy, W. (1976) · PsycEXTRA Dataset · doi:10.1037/e591322011-001 · Cited by 1,896
Diagnosis and definition of treatment-resistant depression
Fava, M. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(03)00231-2 · Cited by 1,380
The Clinical Opiate Withdrawal Scale (COWS)
Wesson, D. R., & Ling, W. (2003) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2003.10400007 · Cited by 1,120
Bupropion-SR, Sertraline, or Venlafaxine-XR after Failure of SSRIs for Depression
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Stewart, J. W., Nierenberg, A. A., Thase, M. E., Ritz, L., Biggs, M. M., Warden, D., Luther, J. F., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052963 · Cited by 1,033 · cited 1×
“While therapeutic strategies such as switching antidepressants and using adjuvant drug treatments can improve response, almost 40% of patients remain symptomatic and fail to achieve full remission (5, 6).”
BackgroundSelf-citationMedication Augmentation after the Failure of SSRIs for Depression
Trivedi, M. H., Fava, M., Wisniewski, S. R., Thase, M. E., Quitkin, F., Warden, D., Ritz, L., Nierenberg, A. A., Lebowitz, B. D., Biggs, M. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052964 · Cited by 1,002
Self-citationAssessing Psychiatric Impairment in Primary Care with the Sheehan Disability Scale
Leon, A. C., Olfson, M., Portera, L., Farber, L., & Sheehan, D. V. (1997) · The International Journal of Psychiatry in Medicine · doi:10.2190/t8em-c8yh-373n-1uwd · Cited by 987 · cited 2×
“No statistically significant differences were observed for either of the buprenorphine/samidorphan dosage groups 504 ajp.psychiatryonline.org Am J Psychiatry 173:5, May 2016 compared with the placebo group on the Inventory of Depressive Symptomatology–Self-Report, the Sheehan Disability Scale, or the SF-12.”
MethodOpioid receptors: Distinct roles in mood disorders
Lutz, P.-E., & Kieffer, B. L. (2013) · Trends in Neurosciences · doi:10.1016/j.tins.2012.11.002 · Cited by 542 · cited 1×
“Since that time, the monoamine hypotheses for the pathophysiology of depression notwithstanding, a growing body of preclinical and clinical evidence supporting the hypothesis that mood disorders involve dysregulation of the endogenous m- and k-opioid system has emerged (7, 9, 10).”
BackgroundFava, M., Evins, A. E., Dorer, D. J., & Schoenfeld, D. A. (2003) · Psychotherapy and Psychosomatics · doi:10.1159/000069738 · Cited by 452
Regulation of Human Affective Responses by Anterior Cingulate and Limbic µ-Opioid Neurotransmission
Zubieta, J.-K., Ketter, T. A., Bueller, J. A., Xu, Y., Kilbourn, M. R., Young, E. A., & Koeppe, R. A. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.11.1145 · Cited by 377
Spielmans, G. I., Berman, M. I., Linardatos, E., Rosenlicht, N. Z., Perry, A., & Tsai, A. C. (2013) · PLoS Medicine · doi:10.1371/journal.pmed.1001403 · Cited by 275
Undurraga, J., & Baldessarini, R. J. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.306 · Cited by 269 · cited 1×
“Clinical trials in depression have been afflicted by increasing rates of placebo response (23).”
BackgroundRegionally selective increases in μ opioid receptor density in the brains of suicide victims
Gross-Isseroff, R., Dillon, K. A., Israeli, M., & Biegon, A. (1990) · Brain Research · doi:10.1016/0006-8993(90)91301-v · Cited by 222
Karp, J. F., Butters, M. A., Begley, A. E., Miller, M. D., Lenze, E. J., Blumberger, D. M., Mulsant, B. H., & Reynolds, C. F. (2014) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.13m08725 · Cited by 191
Evaluation of Opioid Modulation in Major Depressive Disorder
Ehrich, E., Turncliff, R., Du, Y., Leigh-Pemberton, R., Fernandez, E., Jones, R., & Fava, M. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2014.330 · Cited by 169 · cited 4×
“A subsequent small 1-week pilot study characterized the efficacy signal of an 8 mg/8 mg dosage of buprenorphine/ samidorphan after 1 week of adjunctive treatment in patients with major depression who had an inadequate response to standard antidepressants (22).”
BackgroundInfluentialSelf-citationRibeiro, S. C. M., Kennedy, S. E., Smith, Y. R., Stohler, C. S., & Zubieta, J. (2005) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2005.08.011 · Cited by 167
Prescription Opioid Analgesics Increase the Risk of Depression
Scherrer, J. F., Svrakic, D. M., Freedland, K. E., Chrusciel, T., Balasubramanian, S., Bucholz, K. K., Lawler, E. V., & Lustman, P. J. (2014) · Journal of General Internal Medicine · doi:10.1007/s11606-013-2648-1 · Cited by 165 · cited 1×
“Interestingly, there is epidemiologic evidence that chronic high-dosage opioid agonist therapy may increase the risk of depression (18).”
BackgroundChandler, G. M., Iosifescu, D. V., Pollack, M. H., Targum, S. D., & Fava, M. (2010) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2009.00102.x · Cited by 158
Kappa-opioid ligands in the study and treatment of mood disorders
Carlezon, W. A., Béguin, C., Knoll, A. T., & Cohen, B. M. (2009) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.05.008 · Cited by 156 · cited 1×
“Since that time, the monoamine hypotheses for the pathophysiology of depression notwithstanding, a growing body of preclinical and clinical evidence supporting the hypothesis that mood disorders involve dysregulation of the endogenous m- and k-opioid system has emerged (7, 9, 10).”
BackgroundPsychotherapeutic Benefits of Opioid Agonist Therapy
Tenore, P. L. (2008) · Journal of Addictive Diseases · doi:10.1080/10550880802122646 · Cited by 143 · cited 2×
“Additionally, uncontrolled clinical studies have described the efficacy of low-dosage treatmentwith opioids, including buprenorphine, for treatment-refractory depression (8, 16), whereas treatment with a m-opioid antagonist”
BackgroundFava, M., Mischoulon, D., Iosifescu, D., Witte, J., Pencina, M., Flynn, M., Harper, L., Levy, M., Rickels, K., & Pollack, M. (2012) · Psychotherapy and Psychosomatics · doi:10.1159/000332050 · Cited by 141 · cited 2×
“These results support the premise of the sequential parallel comparison design as a strategy to enhance signal detection in relatively smaller samples, and they are consistent with the finding that signal detection is enhanced inplacebononresponders, as the effect size of buprenorphine/ samidorphan was greater in stag…”
MethodResultBuprenorphine has potent kappa opioid receptor antagonist activity
LEANDER, J. (1987) · Neuropharmacology · doi:10.1016/0028-3908(87)90112-2 · Cited by 140 · cited 1×
“In addition to its effects on m-opioid receptors, buprenorphine has also been shown in vivo to block the action of k-opioid agonists (21) and has been characterized in vitro to be a partial k agonist with low intrinsic activity (19).”
Berrocoso, E., Sanchez-Blazquez, P., Garzon, J., & Mico, J. (2009) · Current Pharmaceutical Design · doi:10.2174/138161209788168100 · Cited by 126 · cited 2×
“Opioids havebeenused for centuries to treatwhat arenow recognized as mood disorders and were recommended for melancholia in the 19th and early 20th centuries until they were displaced in the 1950s by monoamine-based antidepressants (7, 8).”
BackgroundTerenius, L. Y., Wahlstr�m, A., & �gren, H. (1977) · Psychopharmacology · doi:10.1007/bf00426537 · Cited by 98
Postmortem μ-opioid receptor binding in suicide victims and controls
Zalsman, G., Molcho, A., Huang, Y., Dwork, A. J., Li, M., & Mann, J. J. (2004) · Journal of Neural Transmission · doi:10.1007/s00702-004-0239-3 · Cited by 96 · cited 1×
“Furthermore, there is evidence of endorphin deficiency in severely depressed and suicidal patients (12, 14, 15).”
BackgroundChen, Y., Yang, Y., Hung, H., & Wang, S. (2011) · Contemporary Clinical Trials · doi:10.1016/j.cct.2011.04.006 · Cited by 86 · cited 1×
“4 resulted in a robust test statistic that demonstrated type I error control, optimal power, and minimum bias under the assumption of missing at random (39).”
BackgroundEffect of inadequate response to treatment in patients with depression.
Knoth, R. L., Bolge, S. C., Kim, E., & Tran, Q.-V. (2010) · PubMed · Cited by 46
Redefining Affective Disorders: Relevance for Drug Development
Targum, S. D., Pollack, M. H., & Fava, M. (2008) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1527-3458.2008.00038.x · Cited by 45 · cited 1×
“DSM-IV-TRAxis I Disorders criteria for a diagnosis ofmajor depressive disorder, which was validated using a SAFER interview administered by remote, independent raters (28).”
MethodSyntheses and opioid receptor binding properties of carboxamido-substituted opioids
Wentland, M. P., Lou, R., Lu, Q., Bu, Y., VanAlstine, M. A., Cohen, D. J., & Bidlack, J. M. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.10.134 · Cited by 43 · cited 2×
“To overcome the limitations of opioid agonists, we developed ALKS 5461—a combination of buprenorphine, which is a partial m-opioid receptor agonist (19), and samidorphan (previously referred to as ALKS 33), which is a potent m-opioid receptor antagonist (20), formulated in a single sublingual tablet.”
BackgroundSynthesis and opioid receptor binding properties of a highly potent 4-hydroxy analogue of naltrexone
Wentland, M. P., Lu, Q., Lou, R., Bu, Y., Knapp, B. I., & Bidlack, J. M. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2005.02.032 · Cited by 41 · cited 1×
“To overcome the limitations of opioid agonists, we developed ALKS 5461—a combination of buprenorphine, which is a partial m-opioid receptor agonist (19), and samidorphan (previously referred to as ALKS 33), which is a potent m-opioid receptor antagonist (20), formulated in a single sublingual tablet.”
BackgroundAsymmetrical distribution of beta-endorphin in cerebral hemispheres of suicides: Preliminary data
Scarone, S., Gambini, O., Calabrese, G., Sacerdote, P., Bruni, M., Carucci, M., & Panerai, A. E. (1990) · Psychiatry Research · doi:10.1016/0165-1781(90)90082-g · Cited by 37 · cited 1×
“Furthermore, there is evidence of endorphin deficiency in severely depressed and suicidal patients (12, 14, 15).”
BackgroundPapakostas, G. I., Vitolo, O. V., IsHak, W. W., Rapaport, M. H., Zajecka, J., Kinrys, G., Mischoulon, D., Lipkin, S., Hails, K. A., Abrams, J., et al. (2012) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.12m07670 · Cited by 32 · cited 1×
“This design was first proposed for use in depression clinical studies (24) to enhance signal detection by reducing placebo response while increasing study efficiency (25, 26).”
MethodSubjective effects of narcotic antagonists.
Haertzen, C. A. (1973) · PubMed · Cited by 24
Jeon, H. J., D, M. F. M., Mischoulon, D., Baer, L., Clain, A. J., Doorley, J. D., DiPierro, M., Cardoos, A., & Papakostas, G. I. (2014) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000039 · Cited by 6 · cited 1×
“This design was first proposed for use in depression clinical studies (24) to enhance signal detection by reducing placebo response while increasing study efficiency (25, 26).”
Method
Research works printed but not linked: 3
- Knoth RL, 2010, Am J Manag Care, 16, e188
- 10.1111/j.1755-5949.2008.00038.x · doi:10.1111/j.1755-5949.2008.00038.x
- Haertzen CA, 1973, Adv Biochem Psychopharmacol, 8, 383
Cited by
Otte, C., Gold, S. M., Penninx, B. W., Pariante, C. M., Etkin, A., Fava, M., Mohr, D. C., & Schatzberg, A. F. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.65 · Cited by 2,269
The Link between Depression and Chronic Pain: Neural Mechanisms in the Brain
Sheng, J., Liu, S., Wang, Y., Cui, R., & Zhang, X. (2017) · Neural Plasticity · doi:10.1155/2017/9724371 · Cited by 775
Attenuation of Antidepressant Effects of Ketamine by Opioid Receptor Antagonism
Williams, N. R., Heifets, B. D., Blasey, C., Sudheimer, K., Pannu, J., Pankow, H., Hawkins, J., Birnbaum, J., Lyons, D. M., Rodriguez, C. I., et al. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2018.18020138 · Cited by 519
“Moreover, buprenorphine, a mu opioid receptor partial agonist and a kappa opioid receptor antagonist, has been shown to produce antidepressant effects (41, 42), even in individuals who have failed to benefit from ECT (43).”
Prognosis and improved outcomes in major depression: a review
Kraus, C., Kadriu, B., Lanzenberger, R., Zarate, C. A., & Kasper, S. (2019) · Translational Psychiatry · doi:10.1038/s41398-019-0460-3 · Cited by 482
Management of Treatment-Resistant Depression: Challenges and Strategies
Voineskos, D., Daskalakis, Z. J., & Blumberger, D. M. (2020) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s198774 · Cited by 446
“These novel combination compounds were deemed tolerable and did not result in opioid withdrawal or tolerance and induced a moderate antidepressant effect, 33 showing most promise as an adjunctive therapy.”
Metadata
- Authors
- Fava, M., Memisoglu, A., Thase, M. E., Bodkin, J. A., Trivedi, M. H., de Somer, M., Du, Y., Leigh-Pemberton, R., DiPetrillo, L., Silverman, B., & Ehrich, E.
- Affiliations
- From the Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston; Alkermes, Inc., Waltham, Mass.; the Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia; McLean Hospital, Belmont, Mass.; and the Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas.
- Harvard University (US)
- Venue
- American Journal of Psychiatry
- Published
- 2016-05-01
- Volume
- 173
- Issue
- 5
- Pages
- 499-508
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W2269913603
- Cited by
- 232
- References
- 40
- Citations by year
- 2026: 7 · 2025: 9 · 2024: 7 · 2023: 12 · 2022: 11 · 2021: 67 · 2020: 20 · 2019: 29 · 2018: 39 · 2017: 20 · 2016: 11
- FWCI
- 26.42
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- American Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Agency for Healthcare Research and Quality
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Keywords
- major depressive disorder, inadequate response to antidepressants, adjunctive therapy, opioid modulation, endogenous opioid system, antidepressant efficacy, drug tolerability
- MeSH terms
- Adolescent, Adult, Aged, Antidepressive Agents, Buprenorphine, Major Depressive Disorder, Double-Blind Method, Drug Combinations, Female, Humans, Male, Middle Aged, Naltrexone, Narcotic Antagonists, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.